CG Oncology, Inc. AI Stock Analysis
Want to see CGON full AI Analyst Report?
CG Oncology, Inc. (CGON) AI Stock Analysis
CG Oncology, Inc.
(NASDAQ:CGON)
The score is driven by strong technical momentum and a highly positive Phase 3 trial catalyst, supported by a low-debt balance sheet. These positives are tempered by very weak current financial performance, including collapsing revenue, large operating losses, and substantial ongoing cash burn, while valuation inputs are limited due to negative earnings and no dividend yield.
CG Oncology, Inc. (CGON) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $7.05B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.18M
- Price to Earnings (P/E)
- -28.4
- Beta (1Y)
- 1.56
- Revenue Growth
- 183.62%
- EPS Growth
- -39.33%
- Country
- US
- Employees
- 142
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CG Oncology, Inc. Business Overview & Revenue Model
Company Description
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigationa...
CG Oncology, Inc. Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is a clear strength with very low leverage (debt-to-equity ~0.009) and substantial assets/equity, but operating performance is weak: TTM revenue is small ($6.2M) and sharply down (-99.6% growth), profitability is deeply negative (TTM EBIT -$264.7M; net loss -$180.6M), and cash flow shows heavy burn (TTM FCF -$189.2M).
Income Statement
12Very NegativeBalance Sheet
74PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.17M | 4.04M | 1.14M | 204.00K | 191.00K | 10.36M |
| Gross Profit | -6.30M | -607.00K | -80.96M | -45.55M | 176.00K | 10.35M |
| EBITDA | -233.76M | -159.55M | -88.01M | -48.59M | -35.43M | -12.38M |
| Net Income | -237.46M | -161.00M | -88.04M | -48.61M | -35.44M | -12.84M |
Balance Sheet | ||||||
| Total Assets | 1.05B | 791.59M | 754.80M | 199.30M | 147.75M | 58.69M |
| Cash, Cash Equivalents and Short-Term Investments | 984.46M | 742.15M | 742.00M | 187.67M | 143.48M | 53.61M |
| Total Debt | 9.24M | 7.02M | 238.00K | 1.03M | 15.94M | 15.13M |
| Total Liabilities | 55.70M | 38.99M | 21.42M | 14.51M | 22.57M | 18.44M |
| Stockholders Equity | 990.97M | 752.60M | 733.38M | 184.79M | 125.18M | 40.25M |
Cash Flow | ||||||
| Free Cash Flow | -189.17M | -132.48M | -78.95M | -45.68M | -29.82M | -13.75M |
| Operating Cash Flow | -187.28M | -132.35M | -78.71M | -45.68M | -29.80M | -13.65M |
| Investing Cash Flow | -333.89M | -245.82M | -300.76M | -121.19M | -55.35M | -97.00K |
| Financing Cash Flow | 504.27M | 153.59M | 628.28M | 87.00M | 119.69M | 15.45M |
CG Oncology, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Positive. The current price of 78.94 is above the 20-day moving average (MA) of 68.29, above the 50-day MA of 68.35, and above the 200-day MA of 66.96, indicating a bullish trend. The MACD of 3.26 indicates Negative momentum. The RSI at 61.68 is Neutral, neither overbought nor oversold. The STOCH value of 62.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGON.
CG Oncology, Inc. Risk Analysis
CG Oncology, Inc. disclosed 82 risk factors in its most recent earnings report. CG Oncology, Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksCG Oncology, Inc. Peers Comparison
Overall Rating
CGON68Neutral
ERAS49Neutral
COGT45Neutral
ORIC44Neutral
RLAY44Neutral
TNGX41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | $7.05B | -28.36 | -24.58% | ― | 183.62% | -39.33% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $4.87B | -14.04 | -61.67% | ― | ― | -120.99% | |
| 45Neutral | $4.85B | -12.01 | -71.13% | ― | ― | 0.71% | |
| 44Neutral | $831.45M | -5.35 | -40.99% | ― | ― | 15.37% | |
| 44Neutral | $3.64B | -10.95 | -40.25% | ― | 23.86% | 13.76% | |
| 41Neutral | $3.75B | -16.17 | -30.34% | ― | -100.00% | -49.92% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CGON | CG Oncology, Inc. | 78.94 | 36.34 | 85.31% | |
| COGT | Cogent Biosciences, Inc. | 27.85 | -7.09 | -20.29% | |
| ORIC | Oric Pharmaceuticals Inc | 8.00 | -3.48 | -30.31% | |
| RLAY | Relay Therapeutics Inc | 16.47 | 10.13 | 159.78% | |
| TNGX | Tango Therapeutics, Inc. | 22.11 | 13.83 | 167.03% | |
| ERAS | Erasca, Inc. | 13.89 | 11.13 | 403.26% |
CG Oncology, Inc. Corporate Events
CG Oncology Reports Positive Phase 3 Bladder Cancer Trial Results
PositiveOn November 16, 2026, CG Oncology announced topline results from its Phase 3 PIVOT-006 registrational trial of adjuvant intravesical cretostimogene in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer following comp...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 16, 2026
